3 completed, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Antares Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study of ATRS-2002 in Healthy Male Adults Abiraterone Acetate - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Withdrawn | Syneos Health | 2022-09-01 | 2023-04-28 | |
| Pharmacokinetic Study of Subcutaneous Testosterone Enanthate Testosterone enanthate auto-injector - Hypogonadism | Phase 1 | Completed | Antares Pharma Inc. | 12 | 2014-09-01 | 2019-04-19 |
| Pharmacokinetic Study of Testosterone Enanthate QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C - Hypogonadism | Phase 1 / Phase 2 | Completed | Antares Pharma Inc. | 39 | 2013-09-01 | 2018-01-11 |
| Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration Methotrexate (MTX) - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | Antares Pharma Inc. | 38 | 2011-01-01 | 2014-02-25 |
Hypogonadism (2) · Arthritis, Rheumatoid (1)
Abiraterone Acetate (1) · Methotrexate (1) · Testosterone (1) · testosterone enanthate (1)
United States (3)
Alan J Kivitz, MD;CPI (1) · Gary Bedel, MD (1) · Jonathan Jaffe, MD (1)